Mohammed Al-Omran

MD, FRCSC, MSc

Scientist, Keenan Research Centre for Biomedical Science

Biography

Dr. Mohammed Al-Omran is a Vascular Surgeon and a Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. He is a Professor at the University of Toronto in the Department of Surgery and an Associate Member at the Institute of Medical Science (IMS). His research interests include: atherosclerosis bench to bedside with special interest in peripheral arterial disease; clinical epidemiology and health services research with a focus on using large healthcare administrative databases to conduct population-based analyses of individuals with aortic, carotid, and peripheral arterial disease; knowledge translation; and systematic reviews and meta-analyses.

Dr. Al-Omran has published widely in high-impact peer-reviewed journals such as the New England Journal of Medicine, Circulation and the Journal of Vascular Surgery. Dr. Al-Omran has been the recipient of several teaching and research awards, and he has supervised research trainees of all levels including: undergraduate, graduate, and post-graduate fellows. He currently serves as the Head of the Division of Vascular Surgery at St. Michael’s Hospital (2013-present) and his clinical practice is focused on management of rare vascular diseases such as thoracic outlet syndrome and carotid body tumors.

Recent Publications

  1. Luu, VZ, Luu, AZ, Chowdhury, B, Elbardisy, O, Pan, Y, Al-Omran, M et al.. Disruption of endothelial cell intraflagellar transport protein 88 exacerbates doxorubicin-induced cardiotoxicity. Life Sci. 2020; :118216. doi: 10.1016/j.lfs.2020.118216. PubMed PMID:32768582 .
  2. Syed, MH, Salata, K, Hussain, MA, Zamzam, A, de Mestral, C, Wheatcroft, M et al.. The economic burden of inpatient diabetic foot ulcers in Toronto, Canada. Vascular. 2020; :1708538120923420. doi: 10.1177/1708538120923420. PubMed PMID:32379584 .
  3. Salata, K, Hussain, MA, Al-Omran, M. Letter by Salata et al Regarding Article, "Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data". Circ Cardiovasc Qual Outcomes. 2020;13 (5):e006569. doi: 10.1161/CIRCOUTCOMES.120.006569. PubMed PMID:32366115 .
  4. Zamzam, A, Syed, MH, Rand, ML, Singh, K, Hussain, MA, Jain, S et al.. Altered coagulation profile in peripheral artery disease patients. Vascular. 2020;28 (4):368-377. doi: 10.1177/1708538120915997. PubMed PMID:32252612 .
  5. Salata, K, Abdallah, FW, Hussain, MA, de Mestral, C, Greco, E, Aljabri, B et al.. Short-term outcomes of combined neuraxial and general anaesthesia versus general anaesthesia alone for elective open abdominal aortic aneurysm repair: retrospective population-based cohort study. Br J Anaesth. 2020;124 (5):544-552. doi: 10.1016/j.bja.2020.01.018. PubMed PMID:32216957 .
  6. Rokoszak, V, Syed, MH, Salata, K, Greco, E, de Mestral, C, Hussain, MA et al.. A systematic review and meta-analysis of plain versus drug-eluting balloon angioplasty in the treatment of juxta-anastomotic hemodialysis arteriovenous fistula stenosis. J. Vasc. Surg. 2020;71 (3):1046-1054.e1. doi: 10.1016/j.jvs.2019.07.075. PubMed PMID:32089200 .
  7. Salata, K, Hussain, MA, de Mestral, C, Greco, E, Awartani, H, Aljabri, BA et al.. Population-based long-term outcomes of open versus endovascular aortic repair of ruptured abdominal aortic aneurysms. J. Vasc. Surg. 2020;71 (6):1867-1878.e8. doi: 10.1016/j.jvs.2019.06.212. PubMed PMID:32085959 .
  8. Verma, S, Ji, Q, Bhatt, DL, Mazer, CD, Al-Omran, M, Inzucchi, SE et al.. Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. Diabetes Obes Metab. 2020;22 (7):1207-1214. doi: 10.1111/dom.13991. PubMed PMID:32030863 PubMed Central PMC7317186.
  9. Alhaizaey, A, Aljabri, B, Alghamdi, M, AlAhmari, A, Abulyazied, A, Asiry, M et al.. Delayed Aortic Stent Collapse in Blunt Traumatic Aortic Injury Repair. Aorta (Stamford). 2019;7 (5):129-136. doi: 10.1055/s-0039-3401022. PubMed PMID:32018308 PubMed Central PMC7000265.
  10. Chowdhury, B, Luu, AZ, Luu, VZ, Kabir, MG, Pan, Y, Teoh, H et al.. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun. 2020;524 (1):50-56. doi: 10.1016/j.bbrc.2020.01.015. PubMed PMID:31980166 .
Search PubMed

Affiliations & Other Activities

  • Head, Division of Vascular Surgery, St. Michael’s Hospital
  • Professor, Department of Surgery, University of Toronto
  • Associate Member, Institute of Medical Sciences, University of Toronto
  • Professor, Department of Surgery, King Saud University
X